In long-interval group, 59.0% of patients experienced at least one adverse events, with the most common being anemia (41.0%), leukopenia (16.4%), increased alanine transaminase (16.4%), neutropenia (13.1%) and thyroid dysfunction (9.8%). This evidence concerns the gene GPT and anemia (phenotype).